Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation
While 91% of organizations were successful in increasing security as a result of adopting cloud services, it remains a top concern for many. This finding comes from part two of the four-part Cloud Impact Study from Aptum, the global hybrid multi-cloud managed service provider. The report, titled The Security and Compliance Barricade , identifies common security, compliance and governance challenges impacting organizations undergoing cloud transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005035/en/
Aptum Cloud Impact Study Pt 2.: The Security and Compliance Barricade (Graphic: Business Wire)
The independent research reveals that more than half of survey respondents (51%) see security as the main driver behind cloud adoption. However, 38% cite security and data protection as the primary barrier to cloud transformation.
Security and compliance play a critical role
Part one of the Cloud Impact Study, Bridging the Cloud Gap , found most survey respondents plan to take a hybridized approach to their cloud infrastructure, with more than half (59%) of respondents saying they will reduce their on-premises infrastructure to some degree and increase public cloud deployments within the next 18-24 months. A further 66% intend to expand their private cloud workloads.
According to data found in today’s report, this expansion and diversification of infrastructure raises security and compliance issues among senior IT professionals, including:
- Control and governance (82%)
- Visibility through a single portal (81%)
- Ability to meet requirements of compliancy audits (80%)
“Organizations are enjoying a newfound agility as they embrace hybrid cloud solutions, but scattered workloads present a security concern," explains Craig Tavares, Global Head of Cloud at Aptum. “A cloud environment is only as secure as the polices and controls an organization has in place, which is why they need to be built into the formation of any cloud strategy. Although no single solution on its own can guarantee 100% security, especially in a multi/hybrid cloud approach, experienced partners can assist organizations in choosing the right combination of security technologies that compliments their workloads no matter where they are hosted and ensure visibility across disparate environments."
“Security teams are tasked with protecting a widening attack surface, often with limited budgets and resources, against bad actors who are employing the same sophisticated techniques as top cybersecurity providers,” said Dan Webb, VP of Partner Sales and Alliances, Alert Logic. “With the ubiquity of cloud and hybrid environments, containerization, and mobile, IoT, and other edge devices, the traditional notion of a perimeter is no more. To be effective, security solutions must enable total visibility across an organization’s IT estate to help organizations quickly identify, prioritize, and respond to all threats that surface.”
Together, Aptum and Alert Logic partner to safeguard business critical data across the infrastructure and application stack, merging security technology, threat intelligence and 24/7 security experts to deliver security outcomes to businesses in an as-a-service model.
The study’s results reinforce the importance of incorporating security into cloud architectures from design through to implementation and transformation. The results call for organizations to take a holistic approach to cloud architectures, with security principles embedded in the design. By doing this, businesses can mitigate threats and minimize risks as they arise to create an environment safer than any on-premise or legacy alternatives.
The full findings of part two of the Cloud Impact Study, The Security and Compliance Barricade, can be found here.
Aptum’s Cloud Impact Study was created from the opinions of 400 senior IT professionals in the US, Canada and UK across industries in financial services, IT, technology, telecommunications, manufacturing, retail, public and commercial sectors. The final two reports will focus on Costs and Budgets and Modernization Opportunities.
For part one of the report, Bridging the Cloud Gap, please visit here.
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Global Network solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America, Europe and the United Kingdom. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
Connect with Aptum
Official Blog| LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005035/en/
Contact information
Media Contact
Tonique Bedeau, Aptum Technologies
media@aptum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
